Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Non-Current Liabilities: 2017-2025

Historic Total Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $386.0 million.

  • Arcus Biosciences' Total Non-Current Liabilities fell 35.56% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $386.0 million, marking a year-over-year decrease of 35.56%. This contributed to the annual value of $508.0 million for FY2024, which is 3.46% up from last year.
  • As of Q3 2025, Arcus Biosciences' Total Non-Current Liabilities stood at $386.0 million, which was up 5.18% from $367.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Total Non-Current Liabilities registered a high of $733.0 million during Q1 2022, and its lowest value of $260.1 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $475.9 million, with a median of $491.0 million in 2023.
  • Per our database at Business Quant, Arcus Biosciences' Total Non-Current Liabilities skyrocketed by 646.09% in 2021 and then crashed by 35.56% in 2025.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Total Non-Current Liabilities stood at $628.4 million in 2021, then decreased by 19.96% to $503.0 million in 2022, then decreased by 2.39% to $491.0 million in 2023, then grew by 3.46% to $508.0 million in 2024, then crashed by 35.56% to $386.0 million in 2025.
  • Its Total Non-Current Liabilities was $386.0 million in Q3 2025, compared to $367.0 million in Q2 2025 and $459.0 million in Q1 2025.